Stealth BioTherapeutics (Stealth BioTherapeutics) EV-to-EBIT : -0.07 (As of May. 26, 2024)

Stealth BioTherapeutics EV-to-EBIT Chart

Stealth BioTherapeutics Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
EV-to-EBIT	Get a 7-Day Free Trial															-1.30	-1.19	-1.00	-0.31	-0.43

Competitive Comparison of Stealth BioTherapeutics's EV-to-EBIT

For the Biotechnology subindustry, Stealth BioTherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stealth BioTherapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stealth BioTherapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Stealth BioTherapeutics's EV-to-EBIT falls into.

Stealth BioTherapeutics EV-to-EBIT Calculation

Stealth BioTherapeutics's EV-to-EBIT for today is calculated as:

Stealth BioTherapeutics's current Enterprise Value is $3.48 Mil.
Stealth BioTherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stealth BioTherapeutics  (NAS:MITO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Stealth BioTherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2022 is calculated as:

Stealth BioTherapeutics's Enterprise Value for the quarter that ended in Mar. 2022 was $21.96 Mil.
Stealth BioTherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stealth BioTherapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Stealth BioTherapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Stealth BioTherapeutics (Stealth BioTherapeutics) Business Description